Adusumilli Prasad S, Chan Mei-Ki, Hezel Michael, Yu Zhenkun, Stiles Brendon M, Chou Ting-Chao, Rusch Valerie W, Fong Yuman
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Ann Surg Oncol. 2007 Jan;14(1):258-69. doi: 10.1245/s10434-006-9127-4. Epub 2006 Nov 1.
Malignant pleural mesothelioma (MPM) treated with radiotherapy (RT) has incomplete responses as a result of radiation-induced tumoral stress response that repairs DNA damage. Such stress response is beneficial for oncolytic viral therapy. We hypothesized that a combination of RT and NV1066, an oncolytic herpes virus, might exert an additive or synergistic effect in the treatment of MPM.
JMN, a MPM cell line, was infected with NV1066 at multiplicities of infection of .05 to .25 in vitro with and without radiation (1 to 5 Gy). Virus replication was determined by plaque assay, cell kill by lactate dehydrogenase assay, and GADD34 (growth arrest and DNA damage repair 34, a DNA damage-repair protein) by real-time reverse transcriptase-polymerase chain reaction and Western blot test. Synergistic cytotoxicity dependence on GADD34 upregulation was confirmed by GADD34 small inhibitory RNA (siRNA).
Synergism was demonstrated between RT and NV1066 across a wide range of doses. As a result of such synergism, a dose-reduction for each agent (up to 5500-fold) can be accomplished over a wide range of therapeutic-effect levels without sacrificing tumor cell kill. This effect is correlated with increased GADD34 expression and inhibited by transfection of siRNA directed against GADD34.
RT can be combined with oncolytic herpes simplex virus therapy in the treatment of malignant pleural mesothelioma to achieve synergistic efficacy while minimizing dosage and toxicity.
接受放射治疗(RT)的恶性胸膜间皮瘤(MPM)由于辐射诱导的肿瘤应激反应修复DNA损伤而反应不完全。这种应激反应有利于溶瘤病毒治疗。我们假设,RT与溶瘤性疱疹病毒NV1066联合使用可能在MPM治疗中发挥相加或协同作用。
MPM细胞系JMN在体外以0.05至0.25的感染复数感染NV1066,同时给予或不给予辐射(1至5 Gy)。通过蚀斑试验测定病毒复制,通过乳酸脱氢酶试验测定细胞杀伤,并通过实时逆转录聚合酶链反应和蛋白质印迹试验测定生长停滞和DNA损伤修复蛋白34(GADD34)。通过GADD34小干扰RNA(siRNA)证实了协同细胞毒性对GADD34上调的依赖性。
在广泛的剂量范围内,RT和NV1066之间表现出协同作用。由于这种协同作用,在不牺牲肿瘤细胞杀伤的情况下,在广泛的治疗效果水平上,每种药物的剂量均可降低(高达5500倍)。这种效应与GADD34表达增加相关,并被针对GADD34的siRNA转染所抑制。
在恶性胸膜间皮瘤的治疗中,RT可与溶瘤性单纯疱疹病毒治疗联合使用,以实现协同疗效,同时将剂量和毒性降至最低。